News Daily News Reassuring Data—and Some Lessons—From Pregnancy-Related SCAD Registry Caitlin E. Cox June 08, 2022
News Conference News EuroPCR 2022 Long-term Outcomes With PCI and CABG: More Analyses to Stir the Pot Michael O'Riordan May 23, 2022
News Conference News ACC 2022 FLAVOUR: FFR as Good as IVUS for Intermediate Coronary Stenoses Michael O'Riordan April 06, 2022
News Daily News Clopidogrel Superior to ‘Divine’ Aspirin Monotherapy in Secondary Prevention Michael O'Riordan March 30, 2022
News Features Bloodlines: How Far Should Cardiologists Go in Treating Family? Todd Neale March 10, 2022
News Daily News Black Patients With Chest Pain Differ From Whites, but Risks Are Similar Michael O'Riordan December 23, 2021
News Features FFR’s Future: Negative Trials Spur Debate Over Technology’s Role Michael O'Riordan December 23, 2021
News Conference News TCT 2021 Debating ISCHEMIA: Do the Results Apply to CABG, Too? Michael O'Riordan November 10, 2021
Presentation TCT 2021 SUGAR: A Randomized Trial of Amphilimus-eluting Stents and Zotarolimus-eluting Stents in Patients With Diabetes Presenter: Rafael Romaguera November 04, 2021
News Conference News TCT 2021 OPTIMIZE: 2-Year DES Data Affirm Need for Meaningful MI Definitions L.A. McKeown October 25, 2021
News Conference News TCT 2021 Good Long-term Results With FANTOM BVS, but More Data Needed Michael O'Riordan October 21, 2021
News Conference News VIVA 2021 EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions L.A. McKeown October 12, 2021
News Conference News VIVA 2021 Diverting or Swirling, New Blood-Flow Tech Shows Promise for CLTI L.A. McKeown October 08, 2021
News Daily News Cardiac Deaths and Adverse Events After PCI Have Declined With Time L.A. McKeown October 05, 2021
News Features Expired Cardiac Devices May Do Global Good, but Safety Unknown Yael L. Maxwell August 26, 2021
News Conference News EAS 2021 High Ischemic Risk and Bleeding Risk: A Delicate Balance Post-PCI Michael O'Riordan June 08, 2021
News Daily News Add-on CMS Payment Sweetens Shockwave Choice, but Cost Still Rankles Michael O'Riordan May 12, 2021